Literature DB >> 12569633

[Clinical study on antibodies against EBV in sera of patients with rheumatoid arthritis].

X Zhang1, B Li, Y Liu, M Jiang.   

Abstract

OBJECTIVE: Study on the relationship between the infection of Epstein-Barr virus (EBV) and the pathogenesis of rheumatoid arthritis (RA).
METHODS: The IgA and IgG antibodies against EBV capsid antigen (IgA/VCA and IgG/VCA respectively), and anti-Z protein IgG antibodies (IgG/Z) in the sera from the patients with RA, systemic lupus erythematosus (SLE), and normal controls were detected by using indirect immunofluoresence and immunobloting techniques.
RESULTS: The positive rate of IgA/VCA antibody in the serum of RA patients which was significantly higher than that in SLE patients and normal subjects. The anti IgG/Z antibodies were only found in RA patients with IgA/VCA antibody.
CONCLUSIONS: The results suggested that activated EB virus may play a role in the pathogenesis of RA. It is a useful laboratory method for the clinical diagnosis of RA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 12569633

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  3 in total

Review 1.  Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus.

Authors:  Peter Hanlon; Alison Avenell; Lorna Aucott; Mark A Vickers
Journal:  Arthritis Res Ther       Date:  2014-01-06       Impact factor: 5.156

Review 2.  Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis.

Authors:  Robert J Ball; Alison Avenell; Lorna Aucott; Peter Hanlon; Mark A Vickers
Journal:  Arthritis Res Ther       Date:  2015-09-29       Impact factor: 5.156

3.  The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis.

Authors:  Zhao-Xia Li; Shan Zeng; Hui-Xia Wu; Yi Zhou
Journal:  Clin Exp Med       Date:  2018-10-25       Impact factor: 3.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.